407 A phase 1b KEYNOTE-B79 trial evaluating non-gene edited allogeneic CAR T-cells, CYAD-101, post FOLFOX preconditioning, followed by pembrolizumab, in refractory metastatic colorectal cancer patients

• David Gilham,
• Caroline Lonez,
• Anne Flament,
• Frédéric Lehmann,
• Erik Alcantar-Orozco,
• Emilie Cerf,
• Charles Morris

Affiliations

David Gilham

Aff4 grid.462482.e0000000404170074Clinical and Experimental Immunotherapy Group, Institute of Cancer SciencesManchester Academic Healthcare Science Centre Manchester United Kingdom

Caroline Lonez

Celyad SA, Mont-Saint-Guibert, Belgium

Anne Flament

Celyad Oncology, Mont-Saint-Guibert, Belgium

Frédéric Lehmann

Celyad Oncology, Mont-Saint-Guibert, Belgium

Erik Alcantar-Orozco

Celyad Oncology, Mont-Saint-Guibert, Belgium

Emilie Cerf

Celyad Oncology, Mont-Saint-Guibert, Belgium

Charles Morris

Celyad Oncology, Mont-Saint-Guibert, Belgium